Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 430

1.

Too fast to stay on track? Shorter time to first anti-retroviral regimen is not associated with better retention in care in the French Dat'AIDS cohort.

Cuzin L, Cotte L, Delpierre C, Allavena C, Valantin MA, Rey D, Delobel P, Pugliese P, Raffi F, Cabié A; Dat’AIDS Study group.

PLoS One. 2019 Sep 6;14(9):e0222067. doi: 10.1371/journal.pone.0222067. eCollection 2019.

2.

Early diagnosis and risk factors of acute hepatitis c in high-risk men who have sex with men on pre-exposure prophylaxis.

Gras J, Mahjoub N, Charreau I, Cotte L, Tremblay C, Chas J, Raffi F, Cua E, Guillon B, Guigue N, Chaix ML, Meyer L, Molina JM, Delaugerre C; and the Ipergay study group.

AIDS. 2019 Sep 2. doi: 10.1097/QAD.0000000000002364. [Epub ahead of print]

PMID:
31483372
3.

Cryptosporidiosis and microsporidiosis as causes of diarrhea in kidney and/or pancreas transplant recipients.

Deltombe C, Lefebvre M, Morio F, Boutoille D, Imbert BM, Le Pape P, Raffi F, Hourmant M.

Med Mal Infect. 2019 Aug 28. pii: S0399-077X(18)30713-3. doi: 10.1016/j.medmal.2019.07.010. [Epub ahead of print]

PMID:
31472993
4.

Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective study-authors' response.

Chauveau M, Raffi F, Allavena C.

J Antimicrob Chemother. 2019 Aug 19. pii: dkz351. doi: 10.1093/jac/dkz351. [Epub ahead of print] No abstract available.

PMID:
31424548
5.

Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial.

Gatell JM, Morales-Ramirez JO, Hagins DP, Thompson M, Arastéh K, Hoffmann C, Raffi F, Osiyemi O, Dretler R, Harvey C, Xu X, Plettenberg A, Smith DE, Portilla J, Rugina S, Kumar S, Frobose C, Wan H, Rodgers A, Hwang C, Teppler H.

Antivir Ther. 2019 Jun 29. doi: 10.3851/IMP3323. [Epub ahead of print]

PMID:
31355775
6.

Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen.

Rizzardini G, Gori A, Miralles C, Olalla J, Molina JM, Raffi F, Kumar P, Antinori A, Ramgopal M, Stellbrink HJ, Das M, Chu H, Ram R, Garner W, Shao Y, Chuck SK, Piontkowsky D, Haubrich RH.

AIDS. 2019 Aug 1;33(10):1583-1593. doi: 10.1097/QAD.0000000000002244.

PMID:
31305329
7.

Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.

Katlama C, Assoumou L, Valantin MA, Soulié C, Martinez E, Béniguel L, Bouchaud O, Raffi F, Molina JM, Fellahi S, Peytavin G, Marcelin AG, Kolta S, Capeau J, Gibowski S, Cardon F, Reynes J, Costagliola D; members of the ANRS 163 ETRAL study .

J Antimicrob Chemother. 2019 Sep 1;74(9):2742-2751. doi: 10.1093/jac/dkz224.

PMID:
31269208
8.

Dual-Specificity Phosphatases in Immunity and Infection: An Update.

Lang R, Raffi FAM.

Int J Mol Sci. 2019 Jun 2;20(11). pii: E2710. doi: 10.3390/ijms20112710. Review.

9.

Community-Based Care in the ANRS-IPERGAY Trial: The Challenges of Combination Prevention.

Puppo C, Mabire X, Cotte L, Castro DR, Spire B, Cua E, Pialoux G, Monti MS, Pasquet A, Raffi F, Molina JM, Préau M; ANRS-Ipergay Study Group.

AIDS Educ Prev. 2019 Jun;31(3):259-272. doi: 10.1521/aeap.2019.31.3.259.

PMID:
31145006
10.

HIV-infected patients aged above 75years.

Bernaud C, Sécher S, Michau C, Perre P, Fialaire P, Vatan R, Raffi F, Allavena C, Hitoto H.

Med Mal Infect. 2019 May 11. pii: S0399-077X(17)30844-2. doi: 10.1016/j.medmal.2019.04.001. [Epub ahead of print]

PMID:
31088755
11.

Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study.

Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, Corbelli GM, Estrada V, Geretti AM, Beloukas A, Raben D, Coll P, Antinori A, Nwokolo N, Rieger A, Prins JM, Blaxhult A, Weber R, Van Eeden A, Brockmeyer NH, Clarke A, Del Romero Guerrero J, Raffi F, Bogner JR, Wandeler G, Gerstoft J, Gutiérrez F, Brinkman K, Kitchen M, Ostergaard L, Leon A, Ristola M, Jessen H, Stellbrink HJ, Phillips AN, Lundgren J; PARTNER Study Group.

Lancet. 2019 Jun 15;393(10189):2428-2438. doi: 10.1016/S0140-6736(19)30418-0. Epub 2019 May 2.

12.

Diabetes and dyslipidaemia are associated with oxidative stress independently of inflammation in long-term antiretroviral-treated HIV-infected patients.

Bastard JP, Couffignal C, Fellahi S, Bard JM, Mentre F, Salmon D, Katlama C, Raffi F, Leport C, Capeau J; ANRS CO, APROCO-COPILOTE Cohort study group.

Diabetes Metab. 2019 Mar 9. pii: S1262-3636(19)30055-2. doi: 10.1016/j.diabet.2019.02.008. [Epub ahead of print]

PMID:
30862472
13.

Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study.

Lê MP, Valantin MA, Assoumou L, Soulie C, Le Mestre S, Weiss L, Yazdanpanah Y, Molina JM, Bouchaud O, Raffi F, Reynes J, Calvez V, Marcelin AG, Costagliola D, Katlama C, Peytavin G; ANRS-163 ETRAL study group.

Pharmacotherapy. 2019 Apr;39(4):514-520. doi: 10.1002/phar.2242. Epub 2019 Apr 1.

PMID:
30815916
14.

Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.

Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, De Ledinghen V, Larrey D, Haour G, Bronowicki JP, Zoulim F, Asselah T, Marcellin P, Thabut D, Leroy V, Tran A, Habersetzer F, Samuel D, Guyader D, Chazouilleres O, Mathurin P, Metivier S, Alric L, Riachi G, Gournay J, Abergel A, Cales P, Ganne N, Loustaud-Ratti V, D'Alteroche L, Causse X, Geist C, Minello A, Rosa I, Gelu-Simeon M, Portal I, Raffi F, Bourliere M, Pol S; French ANRS CO22 Hepather cohort.

Lancet. 2019 Apr 6;393(10179):1453-1464. doi: 10.1016/S0140-6736(18)32111-1. Epub 2019 Feb 11.

PMID:
30765123
15.

Anti-gp41 antibody levels reflect HIV viral suppression and cellular reservoir in long-term antiretroviral-treated trial participants.

Delagreverie HM, Grude M, Lambert-Niclot S, Nere ML, Jadand C, Leport C, Raffi F, Ghislain M, Goujard C, Meyer L, Calvez V, Katlama C, Flandre P, Barin F, Delaugerre C.

J Antimicrob Chemother. 2019 May 1;74(5):1389-1394. doi: 10.1093/jac/dkz004.

PMID:
30690509
16.

Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective study.

Chauveau M, Billaud E, Bonnet B, Merrien D, Hitoto H, Bouchez S, Michau C, Hall N, Perez L, Sécher S, Raffi F, Allavena C; COREVIH Pays de la Loire Study Group .

J Antimicrob Chemother. 2019 Apr 1;74(4):1021-1027. doi: 10.1093/jac/dky547.

PMID:
30689937
17.

Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial.

Bernardino JI, Mocroft A, Wallet C, de Wit S, Katlama C, Reiss P, Mallon PW, Richert L, Molina JM, Knobel H, Morlat P, Babiker A, Pozniac A, Raffi F, Arribas JR; NEAT001/ANRS143 Trial Study Group.

PLoS One. 2019 Jan 28;14(1):e0209911. doi: 10.1371/journal.pone.0209911. eCollection 2019.

18.

Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study.

Shili-Masmoudi S, Sogni P, de Ledinghen V, Esterle L, Valantin MA, Poizot-Martin I, Simon A, Rosenthal E, Lacombe K, Pialoux G, Bouchaud O, Gervais-Hasenknoff A, Goujard C, Piroth L, Zucman D, Dominguez S, Raffi F, Alric L, Bani-Sadr F, Lascoux-Combe C, Garipuy D, Miailhes P, Vittecoq D, Duvivier C, Aumaître H, Neau D, Morlat P, Dabis F, Salmon D, Wittkop L; ANRS CO13 HEPAVIH study group.

PLoS One. 2019 Jan 25;14(1):e0211286. doi: 10.1371/journal.pone.0211286. eCollection 2019.

19.

Dolutegravir monotherapy versus dolutegravir/abacavir/lamivudine for virologically suppressed people living with chronic HIV infection: the randomized non-inferiority MONCAY trial.

Hocqueloux L, Raffi F, Prazuck T, Bernard L, Sunder S, Esnault JL, Rey D, Le Moal G, Roncato-Saberan M, Andre M, Billaud E, Valery A, Avettand-Fenoel V, Parienti JJ, Allavena C; MONCAY study group.

Clin Infect Dis. 2019 Jan 2. doi: 10.1093/cid/ciy1132. [Epub ahead of print]

PMID:
30601976
20.

Switching from abacavir/lamivudine plus nevirapine to abacavir/lamivudine/dolutegravir in virologically controlled HIV-infected adults (SWAD study).

Allavena C, Volteau C, André-Garnier E, Guimard T, Hall N, Khatchatourian L, Morrier M, Billaud E, Rodallec A, Reliquet V, Jovelin T, Le Guen L, Perré P, Grégoire M, Raffi F.

Med Mal Infect. 2018 Dec 21. pii: S0399-077X(17)30852-1. doi: 10.1016/j.medmal.2018.11.012. [Epub ahead of print]

PMID:
30583867
21.

Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV/HCV-coinfected patients- ANRS-CO13 HEPAVIH cohort.

Billa O, Chalouni M, Salmon D, Poizot-Martin I, Gilbert C, Katlama C, Neau D, Chas J, Morlat P, Lacombe K, Naqvi A, Barange K, Gervais A, Bouchaud O, Rosenthal E, Lascoux-Combe C, Garipuy D, Alric L, Dominguez S, Vittecoq D, Goujard C, Duvivier C, Aumaitre H, Miailhes P, Zucman D, Simon A, Lazaro E, Raffi F, Esterle L, Wittkop L, Bani-Sadr F; ANRS CO13 HEPAVIH Study Group.

PLoS One. 2018 Dec 18;13(12):e0208657. doi: 10.1371/journal.pone.0208657. eCollection 2018.

22.

Effect of On-Demand Oral Pre-exposure Prophylaxis With Tenofovir/Emtricitabine on Herpes Simplex Virus-1/2 Incidence Among Men Who Have Sex With Men: A Substudy of the ANRS IPERGAY Trial.

Chaix ML, Charreau I, Pintado C, Delaugerre C, Mahjoub N, Cotte L, Capitant C, Raffi F, Cua E, Pialoux G, Tremblay C, Meyer L, Molina JM; ANRS IPERGAY Study Group .

Open Forum Infect Dis. 2018 Nov 8;5(11):ofy295. doi: 10.1093/ofid/ofy295. eCollection 2018 Nov.

23.

Once-daily darunavir/ritonavir 400/100 mg in triple therapy: efficacy and penetration in seminal compartment in ANRS-165 DARULIGHT study.

Lê MP, Chaix ML, Raffi F, Chevret S, Gallien S, Katlama C, Delobel P, Yazdanpanah Y, Saillard J, Molina JM, Peytavin G; ANRS-165 DARULIGHT study group.

Br J Clin Pharmacol. 2019 Jan;85(1):277-280. doi: 10.1111/bcp.13796. Epub 2018 Nov 12. No abstract available.

PMID:
30421447
24.

Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial.

Ammassari A, Stöhr W, Antinori A, Molina JM, Schwimmer C, Domingo P, Thalme A, Di Pietro M, Wallet C, Pozniak A, Richert L, Raffi F; NEAT001/ANRS143 Trial Study Group.

J Acquir Immune Defic Syndr. 2018 Dec 1;79(4):481-490. doi: 10.1097/QAI.0000000000001834.

25.

Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients.

Allavena C, Hanf M, Rey D, Duvivier C, BaniSadr F, Poizot-Martin I, Jacomet C, Pugliese P, Delobel P, Katlama C, Joly V, Chidiac C, Dournon N, Merrien D, May T, Reynes J, Gagneux-Brunon A, Chirouze C, Huleux T, Cabié A, Raffi F; Dat’AIDS study group.

PLoS One. 2018 Sep 21;13(9):e0203895. doi: 10.1371/journal.pone.0203895. eCollection 2018.

26.

Patient-Reported Outcomes in First-Line Antiretroviral Therapy: Results From NEAT001/ANRS143 Trial Comparing Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine or Raltegravir.

George EC, Bucciardini R, Richert L, Dedes N, Fragola V, Nieuwkerk P, Spire B, Volny-Anne A, West B, Molina JM, Horban A, Fox J, Pozniak A, Vella S, Termote M, Raffi F; NEAT 001/ANRS 143 Study Group.

J Acquir Immune Defic Syndr. 2018 Dec 1;79(4):519-526. doi: 10.1097/QAI.0000000000001844.

PMID:
30234665
27.

Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined with Either Raltegravir or Tenofovir Disoproxil Fumarate /Emtricitabine in the Neat 001/Anrs 143 Trial.

Ammassari A, Stöhr W, Antinori A, Molina JM, Schwimmer C, Domingo P, Thalme A, Di Pietro M, Wallet C, Pozniak A, Richert L, Raffi F; and the NEAT 001/ANRS 143 Trial Study Group.

J Acquir Immune Defic Syndr. 2018 Aug 27. doi: 10.1097/QAI.0000000000001834. [Epub ahead of print]

PMID:
30153121
28.

Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1.

Stella-Ascariz N, Montejano R, Rodriguez-Centeno J, Alejos B, Schwimmer C, Bernardino JI, Rodes B, Allavena C, Hoffmann C, Gisslén M, de Miguel R, Esteban-Cantos A, Wallet C, Raffi F, Arribas JR; NEAT 001/ ANRS 143 Study Group.

J Infect Dis. 2018 Oct 5;218(10):1523-1530. doi: 10.1093/infdis/jiy399.

PMID:
29982509
29.

Hepatitis C virus incidence in HIV-infected and in preexposure prophylaxis (PrEP)-using men having sex with men.

Cotte L, Cua E, Reynes J, Raffi F, Rey D, Delobel P, Gagneux-Brunon A, Jacomet C, Palich R, Laroche H, Cabie A, Hoen B, Chidiac C, Pradat P; Dat'AIDS study Group.

Liver Int. 2018 Jun 30. doi: 10.1111/liv.13922. [Epub ahead of print]

PMID:
29959866
30.

Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study.

Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Stephan C, Rockstroh J, Giacomelli A, Vera J, Bernardino JI, Winston A, Saumoy M, Gras J, Katlama C, Pozniak AL; European Network for AIDS Treatment 022 (NEAT022) Study Group .

Clin Infect Dis. 2019 Feb 1;68(4):597-606. doi: 10.1093/cid/ciy505.

PMID:
29912307
31.

Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.

Lê MP, Chaix ML, Chevret S, Bertrand J, Raffi F, Gallien S, El Abbassi EMB, Katlama C, Delobel P, Yazdanpanah Y, Saillard J, Molina JM, Peytavin G; ANRS 165 DARULIGHT Study Group .

J Antimicrob Chemother. 2018 Aug 1;73(8):2120-2128. doi: 10.1093/jac/dky193.

PMID:
29905808
32.

Risk of diabetes in HIV-infected patients is associated with cirrhosis but not with chronic HCV coinfection in a French nationwide HIV cohort.

Provoost A, Dramé M, Cotte L, Cuzin L, Garraffo R, Rey D, Raffi F, Poizot-Martin I, Pugliese P, Bani-Sadr F; Dat'AIDS study group.

Aliment Pharmacol Ther. 2018 Aug;48(3):281-289. doi: 10.1111/apt.14812. Epub 2018 Jun 14.

PMID:
29901821
33.

Characteristics and outcome of multidrug-resistant tuberculosis in a low-incidence area.

Gaborit BJ, Revest M, Roblot F, Maakaroun-Vermesse Z, Bemer P, Guimard T, Raffi F, Bourigault C, Boutoille D; GERICCO MDR-TB study group.

Med Mal Infect. 2018 Oct;48(7):457-464. doi: 10.1016/j.medmal.2018.04.400. Epub 2018 Jun 7.

PMID:
29887187
34.

Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight).

Molina JM, Gallien S, Chaix ML, El Abbassi EM, Madelaine I, Katlama C, Valin N, Delobel P, Desseaux K, Peytavin G, Saillard J, Raffi F, Chevret S; ANRS 165 Darulight Study Group .

J Antimicrob Chemother. 2018 Aug 1;73(8):2129-2136. doi: 10.1093/jac/dky181.

PMID:
29860402
35.

Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial.

Winston A, Post FA, DeJesus E, Podzamczer D, Di Perri G, Estrada V, Raffi F, Ruane P, Peyrani P, Crofoot G, Mallon PWG, Castelli F, Yan M, Cox S, Das M, Cheng A, Rhee MS.

Lancet HIV. 2018 Apr;5(4):e162-e171. doi: 10.1016/S2352-3018(18)30010-9. Epub 2018 Feb 20.

36.

Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV.

Pradat P, Huleux T, Raffi F, Delobel P, Valantin MA, Poizot-Martin I, Pugliese P, Reynes J, Rey D, Hoen B, Cabie A, Bani-Sadr F, Cheret A, Duvivier C, Jacomet C, Fresard A, Hustache-Mathieu L, Cotte L; Dat’AIDS study Group.

AIDS. 2018 May 15;32(8):1077-1082. doi: 10.1097/QAD.0000000000001789.

PMID:
29438195
37.

Acceptability of HIV cure-related trials: the challenges for physicians and people living with HIV (ANRS-APSEC).

Preau M, Doumergue M, Protiere C, Goujard C, Mora M, Meyer L, Lelievre JD, Raffi F, Spire B, Lambotte O, Suzan-Monti M.

AIDS Care. 2018 Jul;30(7):914-920. doi: 10.1080/09540121.2018.1426825. Epub 2018 Jan 18.

PMID:
29347826
38.

Loss of the DNA Damage Repair Kinase ATM Impairs Inflammasome-Dependent Anti-Bacterial Innate Immunity.

Erttmann SF, Härtlova A, Sloniecka M, Raffi FAM, Hosseinzadeh A, Edgren T, Rofougaran R, Resch U, Fällman M, Ek T, Gekara NO.

Immunity. 2017 Dec 19;47(6):1210-1211. doi: 10.1016/j.immuni.2017.11.014. No abstract available.

39.

Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial.

Molina JM, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C, Capitant C, Rojas-Castro D, Fonsart J, Bercot B, Bébéar C, Cotte L, Robineau O, Raffi F, Charbonneau P, Aslan A, Chas J, Niedbalski L, Spire B, Sagaon-Teyssier L, Carette D, Mestre SL, Doré V, Meyer L; ANRS IPERGAY Study Group.

Lancet Infect Dis. 2018 Mar;18(3):308-317. doi: 10.1016/S1473-3099(17)30725-9. Epub 2017 Dec 8.

PMID:
29229440
40.

Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study).

Rosenthal E, Fougerou-Leurent C, Renault A, Carrieri MP, Marcellin F, Garraffo R, Teicher E, Aumaitre H, Lacombe K, Bailly F, Billaud E, Chevaliez S, Dominguez S, Valantin MA, Reynes J, Naqvi A, Cotte L, Metivier S, Leroy V, Dupon M, Allegre T, De Truchis P, Jeantils V, Chas J, Salmon-Ceron D, Morlat P, Neau D, Perré P, Piroth L, Pol S, Bourlière M, Pageaux GP, Alric L, Zucman D, Girard PM, Poizot-Martin I, Yazdanpanah Y, Raffi F, Pabic EL, Tual C, Pailhé A, Amri I, Bellissant E, Molina JM; ANRS HC31 SOFTRIH Study Group.

HIV Med. 2018 Mar;19(3):227-237. doi: 10.1111/hiv.12571. Epub 2017 Dec 7.

PMID:
29214737
41.

HIV is associated with airway obstruction: a matched controlled study.

Makinson A, Hayot M, Eymard-Duvernay S, Ribet C, Raffi F, Pialoux G, Zucman D, Poizot-Martin I, Bonnet F, Abgrall S, Tattevin P, Cheret A, Ferry T, Mauboussin JM, Marchand L, Rouzaud C, Reynes J, Zins M, Le Moing V; ANRS EP48 HIV CHEST study Team.

AIDS. 2018 Jan 14;32(2):227-232. doi: 10.1097/QAD.0000000000001691.

PMID:
29135582
42.

Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen.

Raffi F, Hanf M, Ferry T, Khatchatourian L, Joly V, Pugliese P, Katlama C, Robineau O, Chirouze C, Jacomet C, Delobel P, Poizot-Martin I, Ravaux I, Duvivier C, Gagneux-Brunon A, Rey D, Reynes J, May T, Bani-Sadr F, Hoen B, Morrier M, Cabie A, Allavena C; Dat’AIDS Study Group.

J Antimicrob Chemother. 2017 Dec 1;72(12):3502. doi: 10.1093/jac/dkx383. No abstract available.

PMID:
29121210
43.

Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk.

Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Pozniak AL; NEAT022 Study Group*.

AIDS. 2017 Nov 28;31(18):2503-2514. doi: 10.1097/QAD.0000000000001675.

44.

Patterns of patient and healthcare provider viewpoints regarding participation in HIV cure-related clinical trials. Findings from a multicentre French survey using Q methodology (ANRS-APSEC).

Protière C, Spire B, Mora M, Poizot-Martin I, Préau M, Doumergue M, Morlat P, Zucman D, Goujard C, Raffi F, Lambotte O, Suzan-Monti M.

PLoS One. 2017 Nov 2;12(11):e0187489. doi: 10.1371/journal.pone.0187489. eCollection 2017.

45.

Interest of proviral HIV-1 DNA genotypic resistance testing in virologically suppressed patients candidate for maintenance therapy.

Allavena C, Rodallec A, Leplat A, Hall N, Luco C, Le Guen L, Bernaud C, Bouchez S, André-Garnier E, Boutoille D, Ferré V, Raffi F.

J Virol Methods. 2018 Jan;251:106-110. doi: 10.1016/j.jviromet.2017.10.016. Epub 2017 Oct 16.

PMID:
29042218
46.

Developing a patient-reported outcome measure for HIV care on perceived barriers to antiretroviral adherence: assessing the needs of HIV clinicians through qualitative analysis.

Toupin I, Engler K, Lessard D, Wong L, Lènàrt A, Spire B, Raffi F, Lebouché B.

Qual Life Res. 2018 Feb;27(2):379-388. doi: 10.1007/s11136-017-1711-5. Epub 2017 Oct 13.

PMID:
29027607
47.

Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen.

Raffi F, Hanf M, Ferry T, Khatchatourian L, Joly V, Pugliese P, Katlama C, Robineau O, Chirouze C, Jacomet C, Delobel P, Poizot-Martin I, Ravaux I, Duvivier C, Gagneux-Brunon A, Rey D, Reynes J, May T, Bani-Sadr F, Hoen B, Morrier M, Cabie A, Allavena C; Dat’AIDS Study Group.

J Antimicrob Chemother. 2017 Dec 1;72(12):3425-3434. doi: 10.1093/jac/dkx300. Erratum in: J Antimicrob Chemother. 2017 Dec 1;72(12):3502.

PMID:
28961719
48.

Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients.

Carrieri MP, Protopopescu C, Marcellin F, Rosellini S, Wittkop L, Esterle L, Zucman D, Raffi F, Rosenthal E, Poizot-Martin I, Salmon-Ceron D, Dabis F, Spire B; ANRS CO13 HEPAVIH Study Group.

J Hepatol. 2017 Dec;67(6):1157-1167. doi: 10.1016/j.jhep.2017.08.005. Epub 2017 Sep 21.

PMID:
28942916
49.

Raltegravir becomes a once daily antiretroviral.

Raffi F, Allavena C.

Lancet HIV. 2017 Nov;4(11):e476-e477. doi: 10.1016/S2352-3018(17)30154-6. Epub 2017 Sep 11. No abstract available.

PMID:
28918878
50.

Patient profiles as organizing HIV clinicians' ART adherence management: a qualitative analysis.

Toupin I, Engler K, Lessard D, Wong L, Lènàrt A, Raffi F, Spire B, Lebouché B.

AIDS Care. 2018 Feb;30(2):207-210. doi: 10.1080/09540121.2017.1360995. Epub 2017 Aug 1.

PMID:
28764563

Supplemental Content

Support Center